Article Text

Download PDFPDF

P660 Extra-genital ciprofloxacin-resistant neisseria gonorrhoeae infections among sexual-health clinic users in lima, peru
  1. Silver Vargas1,
  2. Luz Qquellon2,
  3. David Durand3,
  4. Lao-Tzu Allan-Blitz4,
  5. Kelika Konda5,
  6. Carlos Caceres5,
  7. Jeffrey Klausner6
  1. 1Universidad Peruana Cayetano Heredia, School of Public Health and Administration, Lima, Peru
  2. 2Universidad Peruana Cayetano Heredia, Laboratory of Sexual Health, Lima, Peru
  3. 3Universidad Peruana Cayetano Heredia, Laboratory of Pediatric Infectology, Tropical Medicine Institute “Alexander Von Humbolt”, Lima, Peru
  4. 4University of California Los Angeles, Division of Infectious Diseases, David Geffen School of Medicine, Los Angeles, USA
  5. 5Universidad Peruana Cayetano Heredia, Center for Interdisciplinary Studies in Sexuality, AIDS and Society, Lima, Peru
  6. 6UCLA – David Geffen School of Medicine, Infectious Diseases, Los Angeles, USA


Background The increasing prevalence of drug-resistant Neisseria gonorrhoeae (NG) infections has caused great concern. NG susceptibility to ciprofloxacin can be reliably predicted using a real-time polymerase chain reaction (PCR) assay for the determination of mutation at codon 91 of the gyrase A (gyrA) gene. Ciprofloxacin remains the empiric antimicrobial recommended to treat NG infections in Peru, however local data are limited regarding the prevalence of ciprofloxacin resistance.

Methods Clinical swab specimens from pharyngeal and rectal anatomic locations were collected quarterly between 2013 and 2016 from a cohort of men who have sex with men (MSM) and transgender women in Lima, Peru. NG detection was done using Aptima Combo 2 assay (Hologic Inc, USA). NG-Positive samples were selected for DNA extraction using High Pure PCR Template Preparation Kit (Roche Inc, USA). DNA was amplified using a probe-based Real-time PCR assay to determine point mutations at codon 91 of the gyrA gene.

Results Overall, 156 individuals had at least one sample that tested positive for NG by the Aptima assay, 61 (39%) of whom reported a previous sexually transmitted infection diagnosis and 50 (32%) were HIV-infected. Of the 80 participants with gyrA genotype results available, 67 (84%) had at least one sample with a gyrA mutant NG strain; also, 5 individuals alternated between wild type and mutant NG strain infections during follow up in the same anatomical site.

Conclusion We report the prevalence of individuals with extragenital NG infections with a gyrA mutation conferring ciprofloxacin resistance. While most countries of the region recommend ceftriaxone for NG treatment, Peruvian guidelines need to be updated urgently given the high frequency of ciprofloxacin resistance. The use of molecular genetic markers may facilitate surveillance for antimicrobial resistance.

Disclosure No significant relationships.

  • Neisseria gonorrhoeae
  • extragenital
  • antimicrobial resistance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.